Mobile

A specially designed study at many medical sites to compare whether Masitinib in combination with a currently available medicines which are used for first line & second line treatments, namely gemcita...

Mise à jour : Il y a 4 ans
Référence : EUCTR2013-002293-41

A specially designed study at many medical sites to compare whether Masitinib in combination with a currently available medicines which are used for first line & second line treatments, namely gemcitabine or with a currently available series of medicinal treatments (called Folfiri 3), is effective and safe for the treatment of certain types of pancreatic cancer which cannot be removed or is spreading in the body

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To compare efficacy and safety of masitinib in combination with gemcitabine to placebo in combination with gemcitabine, in treatment of patients with advanced/metastatic pancreatic cancer.

Critère d'inclusion

  • Non-resectable locally advanced or metastatic pancreatic cancer

Liens